GenWay Biotech Announces Changes to Board of Directors
GenWay Biotech, a leading provider of protein and antibody solutions, today announced the appointment of Thomas Silberg, President and Chief Executive Officer of GenWay Biotech as Chairman of the Board, and Joseph Panetta, President and Chief Executive Officer (CEO) of BIOCOM and Robert Richard Garber, PhD, Drug Development Consultant as members of the Board of Directors.
Mr. Silberg’s appointment as Chairman of the Board became effective July, 2013. His vision and competent leadership as GenWay Biotech’s President and CEO and member of the Board of Directors since 2010, have proven to be essential for the Company. “I look forward to serving in my new capacity to establish a strong financial future for GenWay and deliver long-term value for customers and shareholders,” said Mr. Silberg. “Although GenWay has an established national and international customer base, we have yet to tap into the wealth of business opportunities in our local San Diego region. We plan on expanding beyond current product offerings by providing options that fulfill unique needs within the biotech industry. I welcome our new board members, Mr. Panetta and Dr. Garber who bring unquestionable knowledge and experience helping to ensure GenWay’s synergy and relevancy within the biotech industry in the years ahead.”
The GenWay Biotech Board of Directors expands from seven to eight members with a new position created specifically for Joseph Panetta, effective November 1, 2013. As President and CEO of BIOCOM, Mr. Panetta is responsible for leadership of the largest regional life science industry association in the U.S. with 600 member companies and firms. “I have admired GenWay’s focus on providing quality technology and service, and sustaining long-term performance over its fifteen years of business,” said Panetta. “I am pleased to leverage my connectivity and serve as a catalyst for GenWay to achieve wider recognition and business success specifically in the San Diego biotech community. “
Filling the open seat on the Board of Directors is Richard Garber, PhD, effective November 1, 2013. Dr. Garber brings over twenty years of experience in education, discovery research, clinical development and medical affairs for therapeutics, devices and diagnostics and how they work together. Dr. Garber holds a Bachelor of Science degree in Biology from Stanford University and a Doctor of Philosophy degree in Biology from Yale University. “Given the evolving industry and competitive landscape in biotechnology, I believe now is the right time for GenWay to explore strategic alternatives for unique product offerings,” said Dr. Garber. “I’m excited to help steer GenWay through this endeavor to provide compelling and exceptional technology for its customers.”
About GenWay Biotech
GenWay Biotech (www.genwaybiotech.com) is a global provider of protein and antibody solutions headquartered in the heart of San Diego’s biotech community in the Sorrento Valley/Mesa area. GenWay’s unique multi-functional technology platform specializes in using genes, proteins, antibodies, and their applications in cells, tissues and animal models for functional genomics and proteomics. The Company provides bioinformatic analyses of protein targets, produces high-quality protein antigens and ligands, and develops domain-specific IgY antibodies for immunoaffinity capture, partitioning, detection and analyses. GenWay also provides downstream proteomic analyses, target validation, and diagnostic product development.